Rxivist logo

The COVID-19 pandemic has had unprecedented health and economic impact, but currently there are no approved therapies. We have isolated an antibody, EY6A, from a late-stage COVID-19 patient and show it neutralises SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds tightly (KD of 2 nM) the receptor binding domain (RBD) of the viral Spike glycoprotein and a 2.6Å crystal structure of an RBD/EY6A Fab complex identifies the highly conserved epitope, away from the ACE2 receptor binding site. Residues of this epitope are key to stabilising the pre-fusion Spike. Cryo-EM analyses of the pre-fusion Spike incubated with EY6A Fab reveal a complex of the intact trimer with three Fabs bound and two further multimeric forms comprising destabilized Spike attached to Fab. EY6A binds what is probably a major neutralising epitope, making it a candidate therapeutic for COVID-19. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 1,205 times
  • Download rankings, all-time:
    • Site-wide: 22,275
    • In microbiology: 1,287
  • Year to date:
    • Site-wide: None
  • Since beginning of last month:
    • Site-wide: 133,062

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide